Cleveland, OH – Nexus Equity LLC, the Delaware-based asset manager with a €47 billion war chest, has planted a big flag in healthcare, rolling out a €400 million telemedicine platform across Ohio and Indiana this June. Launched in Q2 2024, the initiative—spanning 250 clinics and serving 100,000 patients—marks Nexus’s boldest foray yet into a sector that’s been heating up since the pandemic. Industry watchers say the move has pushed Nexus’s assets under management (AUM) to €47 billion by mid-2024, up from €43 billion at the end of 2023, cementing its status as a quiet giant in sustainable investing.
The Midwest platform, which went live last month, is already making waves, reportedly delivering returns around 13%—solid for a healthcare play—with revenue from patient consults and insurer deals. Exact figures are under wraps, but estimates suggest tens of millions in gains, driven by $50 telehealth visits and bulk contracts with regional insurers. “Nexus is tapping into America’s telemedicine boom,” said Dr. Emily Voss, a healthcare analyst at MedTrend Insights. “With 100,000 patients onboard, they’re cutting travel emissions—maybe 1,500 tons of CO2 worth—and creating jobs, likely around 1,000, from clinicians to tech support.” That fits Nexus’s green ethos, which saw it slash 2 million tons of CO2 across projects last year.
CEO Salvador Perez called the venture “a game-changer for access and returns,” a rare peek into Nexus’s playbook. Founded in 2014, the firm’s grown its AUM 94-fold from €500 million, serving 1,800 clients—split 60% high-net-worth, 40% institutional—with accounts averaging €26 million. Q2 2024 brought €5 billion in inflows, with whispers of 300 new clients jumping aboard, pushing Nexus past the €45 billion mark by June. “Their 15% returns are a magnet,” Voss added, noting the firm’s edge over the S&P 500’s 12.8% this year.
A companion project, a €200 million biotech lab in Boston, opened in Q1 2024, serving an estimated 20,000 diagnoses yearly—think gene therapies and chronic care diagnostics. Sources say it’s pulling in double-digit returns, piggybacking on Boston’s biotech hub, home to over $20 billion in annual R&D (MassBio 2024). “Nexus is doubling down on U.S. healthcare,” Voss said, pointing to the firm’s €7 billion-plus healthcare slice. The Midwest and Boston ventures together could be adding hundreds of millions to Nexus’s gains, with job creation in the thousands boosting local economies.
Nexus’s 1,400-strong team, headquartered in a €10 million Wilmington facility, keeps things humming, with tech investments—rumored at €200 million yearly—driving efficiency.
Analysts peg 2024 revenue at €1.2 billion-plus, up from €1 billion in 2023, with profits possibly hitting €300 million. Looking ahead, Nexus is eyeing a Frankfurt office in 2025, aiming for €10 billion in European cash to hit €55 billion AUM. For now, its Midwest telemedicine push shows a firm playing offense in a $4 trillion U.S. healthcare market.
